Trials / Recruiting
RecruitingNCT06476808
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Conditions
- High-grade Serous Ovarian Carcinoma (HGSOC)
- Uterine Serous Carcinoma (USC)
- Non-small Cell Lung Cancer (NSCLC)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986463 | Specified dose on specified days |
Timeline
- Start date
- 2024-09-06
- Primary completion
- 2028-12-19
- Completion
- 2028-12-19
- First posted
- 2024-06-26
- Last updated
- 2026-04-15
Locations
17 sites across 5 countries: United States, Canada, France, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06476808. Inclusion in this directory is not an endorsement.